US Drug Approvals Might Skip Second Trial, Rely More On Clinical Pharmacology
This article was originally published in SRA
Executive Summary
The US Food and Drug Administration is working to provide more clarity on when clinical pharmacology data can serve as the confirmatory evidence needed to approve a drug on the basis of a single pivotal trial.